Michael Brooks, MD
Urology · Houston, TXNPI 1861760969
Payments from drug & device makers
What this record shows
This record is dominated by education: $34,500 of the $46,947 with a category attached, or 73.5%. Intuitive Surgical accounts for 90.2% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2024 at $22,350 and has fallen 68.4% since, to $7,068 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $239.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$42K
- Coloplast$783
- Boston Scientific$587
- Pfizer$410
- Johnson & Johnson$289
- Astellas Pharma US Inc$203
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$1,5003%
- Travel & lodging$4,59610%
- Food & beverage$6,35114%
- Education$34,50073%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 58 | $42,323 |
| Coloplast | 9 | $783 |
| Boston Scientific | 13 | $587 |
| Pfizer | 17 | $410 |
| Johnson & Johnson(2 entities) | 11 | $289 |
| Astellas Pharma US Inc | 9 | $203 |
| Immunitybio, Inc. | 2 | $180 |
| Angiodynamics, Inc. | 5 | $160 |
| Merck | 8 | $155 |
| Koelis Inc. | 1 | $138 |
| Endo Pharmaceuticals Inc. | 6 | $134 |
| Biotissue Holdings Inc. | 3 | $133 |
| Endo USA, Inc. | 5 | $124 |
| Ferring Pharmaceuticals Inc. | 4 | $104 |
| Tempus AI, Inc | 1 | $100 |
| Zimvie Inc. | 1 | $99 |
| ABC Home Medical Supply, Inc. | 5 | $94 |
| Myovant Sciences Inc. | 2 | $88 |
| Myriad Genetic Laboratories, Inc. | 4 | $85 |
| Tolmar, Inc. | 3 | $66 |
| Ambu Inc. | 3 | $63 |
| Medtronic(2 entities) | 3 | $62 |
| Procept Biorobotics Corporation | 2 | $59 |
| Novo Nordisk | 2 | $55 |
| Urogen Pharma, Inc. | 2 | $52 |
| Convatec Inc. | 2 | $48 |
| Hollister Incorporated | 2 | $46 |
| EDAP Technomed Inc | 2 | $43 |
| Teleflex LLC | 1 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Photocure Inc | 1 | $34 |
| Pacira Pharmaceuticals Incorporated | 1 | $27 |
| 180 Medical, Inc. | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Axonics, Inc. | 1 | $21 |
| Heron Therapeutics, Inc. | 1 | $21 |
| AbbVie | 1 | $18 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$36,851
- DA VINCI SP$4,500
- TITAN$425
- Moses 550 DFL$226
- ANKTIVA$154
- Coloplast TFL Drive$145
- TRINITY$138
- Porges Coloplast$137
- GENERAL - THERAPIES$119
How this compares
$46,947 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 101 | $68,990 |
| GemtesaVibegron | 39 | $13,491 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 294 | $6,859 |
| Solifenacin Succinate | 87 | $5,802 |
| Finasteride | 341 | $5,665 |
| Tamsulosin Hcl | 361 | $5,384 |
| Mirabegron ErMirabegron | 12 | $4,904 |
| Testosterone Cypionate | 103 | $2,717 |
| Oxybutynin Chloride ErOxybutynin Chloride | 35 | $1,423 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,186 |
| Testosterone | 14 | $1,074 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $894 |
| NitrofurantoinNitrofurantoin Macrocrystal | 29 | $694 |
| Cefpodoxime Proxetil | 14 | $608 |
| Dutasteride | 14 | $520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $203 | $68,990101 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $40 | $13,49139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 urology providers in Texas.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
- Mohit KheraHouston$428K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.